Project Details
| Status | Active |
|---|---|
| Effective start/end date | 05/8/26 → 11/14/26 |
Funding
- Emalex Biosciences Incorporated: $1.00
WEP Clinical: Emalex Biosciences, Inc - EBS-101-TD-392, An Open Label Expanded Access Program Intended to Provide Treatment with Ecopipam (EBS-101) to Children, Adolescents and Adults in the U.S. with Tourette's Disorder
- Maurer, Carine (PI)
- Schwartz, Guy (CoPI)
Project: Research